UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000011591
Receipt No. R000013552
Scientific Title The role of procalcitonin (PCT) in advanced urological cancer patients with high grade fever
Date of disclosure of the study information 2013/08/28
Last modified on 2013/08/27

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title The role of procalcitonin (PCT) in advanced urological cancer patients with high grade fever
Acronym PCT in advanced urological cancer patients
Scientific Title The role of procalcitonin (PCT) in advanced urological cancer patients with high grade fever
Scientific Title:Acronym PCT in advanced urological cancer patients
Region
Japan

Condition
Condition advanced urological cancer
Classification by specialty
Hematology and clinical oncology Urology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer
Basic objectives2 Others
Basic objectives -Others Diagnostic value
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes comparison of the rate of bacterial infection between defferent PCT levels
Key secondary outcomes the relation between the rate of bacterial infection and other factors such as primary tumor, age, white blood cell count, CRP, body temparature

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria metastatic, locally invasive, or large (longest diameter >5cm, or total of longest diameter >5cm in multiple lesions) urological cancer including urothelial cancer, renal cell cancer, germ cell cancer, prostate cancer, penile cancer, and cancer or sarcoma arisen in genitourinary systems)
Key exclusion criteria patients who did not agree with this study
Target sample size 100

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Kouji Izumi
Organization Kanazawa University Graduate School of Medical Science
Division name Department of Integrative Cancer Therapy and Urology
Zip code
Address 13-1 Takaramachi, Kanazawa, Japan
TEL 076-265-2393
Email azuizu2003@yahoo.co.jp

Public contact
Name of contact person
1st name
Middle name
Last name Kouji Izumi
Organization Kanazawa University Graduate School of Medical Science
Division name Department of Integrative Cancer Therapy and Urology
Zip code
Address 13-1 Takaramachi, Kanazawa, Japan
TEL 076-265-2393
Homepage URL
Email azuizu2003@yahoo.co.jp

Sponsor
Institute Kanazawa University Graduate School of Medical Science, Department of Integrative Cancer Therapy and Urology
Institute
Department

Funding Source
Organization Kanazawa University Graduate School of Medical Science, Department of Integrative Cancer Therapy and Urology
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 石川県立中央病院(石川県)、国立病院機構金沢医療センター(石川県)、富山県立中央病院(富山県)、厚生連高岡病院(富山県)、敦賀市立病院(福井県)、福井済生会病院(福井県)

Other administrative information
Date of disclosure of the study information
2013 Year 08 Month 28 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2013 Year 07 Month 17 Day
Date of IRB
Anticipated trial start date
2013 Year 08 Month 28 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information PCT, CRP, white blood cell, red blood cell, platelet cell, Hb, BUN, Cr, AST, ALT, LDH, AFP, Total protein, albmin, and cultures(sputum, urin, stool), radiological diagnostic modalities (X-ray, CT, MRI, Ga scintigraphy, ultrasound) if needed.

Management information
Registered date
2013 Year 08 Month 27 Day
Last modified on
2013 Year 08 Month 27 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013552

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.